We are improving biopharmaceutical manufacturing by enhancing the production and secretion of recombinant proteins using mammalian cell lines such as Chinese Hamster Ovary (CHO) cells and Human Embryonic Kidney (HEK293) cells. We rely on the ability to make quantitative measurements on gene copy number, gene expression, and genome mutations which has significantly accelerated cellular engineering efforts.

Currently, we are leveraging engineering methods and the desire to perform site-specific integration to increase productivity in monoclonal antibody (mAb), bispecific antibody (BsAb), and adeno-associated viral (AAV) production processes. Some of our group’s work focuses on developing model processes and cell lines through site-specific and transposase-mediated integration methods.